123955-10-2

• 常用中文名：阿莫兰特
• 常用英文名：Almokalant
• CAS号：123955-10-2
• 分子式：C₁₈H₂₈N₂O₃S
• 分子量：352.49200
• 相关类别： 信号通路 跨膜转运 钾通道
• 发布时间：2018-09-02 14:35:27
• 更新时间：2024-01-14 14:57:29
• Almokalant 是一种第三类抗心律失常的药物,为钾离子通道阻滞剂,抑制时间依赖性延迟整流钾离子电流的特有的组分 Ikr。

名称

• 中文名: 阿莫兰特
• 英文名: 4-[3-[ethyl(3-propylsulfinylpropyl)amino]-2-hydroxypropoxy]benzonitrile
• 英文别名: 4-(3-(Ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy)benzonitrile; Benzonitrile,4-(3-(ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy); Almokalantum [INN-Latin]; Almoklant; Almokalant [INN]; (+-)-p-(3-(Ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy)benzonitrile; 4-[3-[ethyl[3-((R*)-propylsulfinyl)propyl]amino]-2(R)-hydroxypropoxy]-benzonitrile; Almokalantum; Almokalant

物化性质

• 密度: 1.17g/cm3
• 沸点: 574.8ºC at 760mmHg
• 分子式: C₁₈H₂₈N₂O₃S
• 分子量: 352.49200
• 闪点: 301.4ºC
• 精确质量: 352.18200
• PSA: 92.77000
• LogP: 3.03438
• 蒸汽压: 4.73E-14mmHg at 25°C
• 折射率: 1.567

生物活性

• 描述: Almokalant 是一种第三类抗心律失常的药物,为钾离子通道阻滞剂,抑制时间依赖性延迟整流钾离子电流的特有的组分 Ikr。
• 相关类别:
  信号通路 >> 跨膜转运 >> 钾通道
  研究领域 >> 心血管疾病
• 靶点:

  Potassium channel[1]

• 体外研究: Almokalant是一种III类抗心律失常药物,可作为钾通道阻滞剂,抑制特定成分(Ikr)的时间依赖性延迟整流钾电流[1]。
• 体内研究: 在第11天给药后,Almokalant(125μmol/ kg,po)在怀孕大鼠中诱导心血管缺陷,口面裂缝和尾部缺陷。Almokalant也在怀孕大鼠中引起[1]。
• 参考文献:

  [1]. Wellfelt K, et al. Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species. Reprod Toxicol. 1999 Mar-Apr;13(2):93-101.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : DI2457916 CHEMICAL NAME : Benzonitrile, 4-(3-(ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxy propoxy)- CAS REGISTRY NUMBER : 123955-10-2 LAST UPDATED : 199806 DATA ITEMS CITED : 4 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 35250 ug/kg SEX/DURATION : female 12 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 53,168,1996 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 70500 ug/kg SEX/DURATION : female 10 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) REFERENCE : TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 53,168,1996 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 35250 ug/kg SEX/DURATION : female 11 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) REFERENCE : TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 53,168,1996 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 17625 ug/kg SEX/DURATION : female 13 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 53,168,1996

合成路线

123955-09-9 ~% 123955-10-2

文献：Aktiebolaget Hassle Patent: US5068272 A1, 1991 ;

107-10-8 70987-79-0 ~% 123955-10-2

文献：Aktiebolaget Hassle Patent: US5055490 A1, 1991 ;

上下游产品

上游产品  3
123955-09-9 107-10-8 70987-79-0
下游产品  0